drugset / Trial / NCT06311656
A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants
Phase 1
Completed
69 enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
RandomizedSequentialDouble-blindBasic science
Summary
The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy asian participants and non-Asian participants. Part A consists of 2 groups and Part B, C, and D include optional groups.
Timeline
- Start
- 2024-03-19
- Primary completion
- 2024-10-04
- Completion
- 2024-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY4100511 | Unknown | — | Oral |
Indications
No indication recorded.